{"content":"<li class=\"n-box-item date-title\" data-end=\"1536465599\" data-start=\"1536379200\" data-txt=\"Monday, December 23, 2019\">Saturday, September  8, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3388902\" data-ts=\"1536429476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSK\" target=\"_blank\">GSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3388902-fda-rejects-glaxos-nucala-in-copd\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA rejects Glaxo&#39;s Nucala in COPD</a></h4><ul><li>GlaxoSmithKline (NYSE:<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a>) has <a href=\"https://www.gsk.com/en-gb/media/press-releases/gsk-receives-complete-response-letter-from-us-fda-for-use-of-mepolizumab-in-copd-patients/\" target=\"_blank\">received </a>a Complete Response Letter &#40;CRL&#41; from the FDA related to its marketing application seeking approval for NUCALA (mepolizumab) as add-on therapy to inhaled corticosteroid-based maintenance treatment for reducing exacerbations in patients with chronic obstructive pulmonary disease &#40;COPD&#41;. The CRL cited the need for additional clinical data.</li><li>NUCALA was approved in the U.S. in November 2015 for severe asthma and in December 2017 for eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).</li></ul><div class=\"tiny-share-widget\" data-id=\"3388902\" data-linked=\"FDA rejects Glaxo&#39;s Nucala in COPD\" data-tweet=\"$GSK - FDA rejects Glaxo&#39;s Nucala in COPD https://seekingalpha.com/news/3388902-fda-rejects-glaxos-nucala-in-copd?source=tweet\" data-url=\"https://seekingalpha.com/news/3388902-fda-rejects-glaxos-nucala-in-copd\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3388901\" data-ts=\"1536428979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYTU\" target=\"_blank\">AYTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3388901-aytu-bio-readies-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aytu Bio readies equity offering</a></h4><ul><li>Aytu BioScience (NASDAQ:<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1385818/000121390018012289/fs12018_aytubioscience.htm\" target=\"_blank\">preliminary prospectus</a> for a public offering of Class A and Class B Units.</li><li>Each Class A Unit will consist of one share of common stock and one warrant to purchase 1/2 of a share of common. Each Class B Unit will consist of one share of Series C Preferred Stock, convertible into one common share, and one warrant to purchase 1/2 of a share of common.</li></ul><div class=\"tiny-share-widget\" data-id=\"3388901\" data-linked=\"Aytu Bio readies equity offering\" data-tweet=\"$AYTU - Aytu Bio readies equity offering https://seekingalpha.com/news/3388901-aytu-bio-readies-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3388901-aytu-bio-readies-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3388900\" data-ts=\"1536428676\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IOVA\" target=\"_blank\">IOVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3388900-iovance-files-for-250m-mixed-shelf-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iovance files for $250M mixed shelf offering</a></h4><ul><li>Iovance Biotherapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/IOVA' title='Iovance Biotherapeutics, Inc.'>IOVA</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1425205/000114420418048591/tv502427_s3.htm\" target=\"_blank\">prospectus </a>for a $250M mixed shelf offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3388900\" data-linked=\"Iovance files for $250M mixed shelf offering\" data-tweet=\"$IOVA - Iovance files for $250M mixed shelf offering https://seekingalpha.com/news/3388900-iovance-files-for-250m-mixed-shelf-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3388900-iovance-files-for-250m-mixed-shelf-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3388899\" data-ts=\"1536426810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMNP\" target=\"_blank\">IMNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3388899-immune-pharmaceuticals-down-6-on-former-ceo-connection-to-alleged-securities-fraud\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immune Pharmaceuticals down 6% on former CEO connection to alleged securities fraud</a></h4><ul><li>Nano cap Immune Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a>) ended Friday's session down&nbsp;<font color='red'>6%&nbsp;</font>on below-average volume in apparent response to the connection of former President &amp; CEO Elliot Maza with SEC charges of alleged securities fraud.</li><li>Mr. Maza had been CEO since September 2017 but <a href=\"https://www.sec.gov/Archives/edgar/data/1208261/000114420418046794/tv501917_8k.htm\" target=\"_blank\">resigned </a>on August 28 ahead of the SEC's <a href=\"https://www.sec.gov/news/press-release/2018-182\" target=\"_blank\">announcement </a>of the charges yesterday.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3388837-sec-charges-frost-honig-stock-promotion-schemes-opko-18-percent\" target=\"_blank\">SEC charges Frost and Honig with stock promotion schemes; OPKO down 18%</a> (Sept. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3388899\" data-linked=\"Immune Pharmaceuticals down 6% on former CEO connection to alleged securities fraud\" data-tweet=\"$IMNP $IMNPQ - Immune Pharmaceuticals down 6% on former CEO connection to alleged securities fraud https://seekingalpha.com/news/3388899-immune-pharmaceuticals-down-6-on-former-ceo-connection-to-alleged-securities-fraud?source=tweet\" data-url=\"https://seekingalpha.com/news/3388899-immune-pharmaceuticals-down-6-on-former-ceo-connection-to-alleged-securities-fraud\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3388898\" data-ts=\"1536425814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LTS\" target=\"_blank\">LTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3388898-ladenburg-thalmann-down-15-on-sec-charges-on-chairman-frost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ladenburg Thalmann down 15% on SEC charges on Chairman Frost</a></h4><ul><li>Financial services firm Ladenburg Thalmann (NYSEMKT:<a href='https://seekingalpha.com/symbol/LTS' title='Ladenburg Thalmann Financial Services Inc.'>LTS</a>) ended Friday's session down&nbsp;<font color='red'>15%</font>&nbsp;on a 9x surge in volume in reaction to Chairman Phillip Frost's alleged involvement in stock promotions as charged by the SEC.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3388837-sec-charges-frost-honig-stock-promotion-schemes-opko-18-percent\" target=\"_blank\">SEC charges Frost and Honig with stock promotion schemes; OPKO down 18%</a> (Sept. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3388898\" data-linked=\"Ladenburg Thalmann down 15% on SEC charges on Chairman Frost\" data-tweet=\"$LTS - Ladenburg Thalmann down 15% on SEC charges on Chairman Frost https://seekingalpha.com/news/3388898-ladenburg-thalmann-down-15-on-sec-charges-on-chairman-frost?source=tweet\" data-url=\"https://seekingalpha.com/news/3388898-ladenburg-thalmann-down-15-on-sec-charges-on-chairman-frost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":5,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}